

Column E Explanations Referencing APHIS Form 7023

**2012 Annual Report of Research Facility
21 November 2012**

1. Registration Number 42-R-0020

2. Number of Animals Used in the Study:

Eighty four (84) used in *Cl. chauvoei* potency assay for release of serials of USDA regulated biological product (i.e. vaccine).

3. Species (common name) of Animals Used in the Study:

Guinea Pig

4. Explanation of Procedure Producing Pain and/or Distress:

Clostridium chauvoei Potency Assay: This test is mandated by APHIS-Center for Veterinary Biologics (CVB) in the licensing of vaccines to protect animals from the effects of disease caused by infection with *Cl. chauvoei*. This test is prescribed in Title 9 of the Code of Federal Regulations.

The test procedure involves the vaccination challenge model which requires that control animals (guinea pigs) succumb to the test challenge, become recumbent and are unable to rise.

As per 9 CFR 117.4 (e), and in accordance with APHIS-CVB communication of April 1, 2004 (RE: VBN 04-09), APHIS-CVB has approved a "non-death" endpoint in our production outlines that allows humane methods of euthanasia.

5. Scientific Justification as to Why Pain and /or Distress Could Not Be Relieved:

This test is codified in the Title 9 Code of Federal Regulations. This codified test method has been promulgated by APHIS-CVB and to date; APHIS-CVB has not published guidance to licensed biological manufacturers that would allow for the use of drugs such as pain relievers to reduce pain and suffering prior to attaining the study endpoint.

To our knowledge, APHIS-CVB has not determined, nor communicated, what impact, use of drugs such as pain relievers would have on the validity of these assays.

In some species of animals, clinical signs indicative of an inevitable progression to death are difficult to assess. To prevent interference with the test objectives, while at the same time promote the most humane treatment/endpoints of test animals permissible, production outlines have been modified to include the humane euthanasia of moribund animals exhibiting clinical signs consistent with disease pathogenesis that are unable to rise or move under their own power.

6. Identification of Federal Regulations Requiring This Procedure:

- USDA (APHIS-CVB): 9 CFR 113.106 (c).

Initials: (b) (6), (b) (7)(C) Date: 21 Nov 2012

Column E Explanations Referencing APHIS Form 7023

**2012 Annual Report of Research Facility
21 November 2012**

1. Registration Number 42-R-0020

2. Number of Animals Used in the Study:

Three Thousand Seven Hundred and Seventeen (3,717)

3. Species (common name) of Animals Used in the Study:

Hamster

4. Explanation of Procedure Producing Pain and/or Distress:

Leptospira sp. Potency Assay: These tests are mandated by APHIS-Center for Veterinary Biologics (CVB) in the licensing of vaccines to protect animals from the effects of disease caused by infection with multiple *Leptospira* species. These tests are prescribed in Title 9 of the Code of Federal Regulations.

As per 9 CFR 117.4 (e), and In accordance with APHIS-CVB communication of April 1, 2004 (RE: VBN 04-09), APHIS-CVB has approved a "non-death" endpoint in our production outlines that allows humane methods of euthanasia.

5. Scientific Justification as to Why Pain and /or Distress Could Not Be Relieved:

These tests are codified in the Title 9 Code of Federal Regulations. These codified tests methods have been promulgated by APHIS-CVB and to date; APHIS-CVB has not published guidance to licensed biological manufacturers that would allow for the use of drugs such as pain relievers to reduce pain and suffering prior to attaining the study endpoint.

To our knowledge, APHIS-CVB has not determined, nor communicated, what impact, use of drugs such as pain relievers would have on the validity of these assays.

In some species of animals, clinical signs indicative of an inevitable progression to death are difficult to assess. To prevent interference with the test objectives, while at the same time promote the most humane treatment/endpoints of test animals permissible, production outlines have been modified to include the humane euthanasia of moribund animals exhibiting clinical signs consistent with disease pathogenesis that are unable to rise or move under their own power.

6. Identification of Federal Regulations Requiring This Procedure:

- USDA (APHIS-CVB): 9 CFR 113.101(c).
- USDA (APHIS-CVB): 9 CFR 113.102(c).
- USDA (APHIS-CVB): 9 CFR 113.103(c).
- USDA (APHIS-CVB): 9 CFR 113.104(c).

Initials: (b)(6), (b)(7)
(c)

Date: 21 Nov 2012

Column E Explanations Referencing APHIS Form 7023

**2012 Annual Report of Research Facility
21 November 2012**

1. Registration Number 42-R-0020

2. Number of Animals Used in the Study:

Two (2)

3. Species (common name) of Animals Used in the Study:

Rabbits

4. Explanation of Procedure Producing Pain and/or Distress:

One rabbit was sick upon arrival to the facilities from the vendor. The animal was placed on treatment; however, he was dead at subsequent observation.

One rabbit died while on Porcine Parvovirus Rabbit Serology Potency Test (Special Outline 8-021; Approved by APHIS CVB on August 9 2011). Death was not expected and therefore the animal was sent for diagnostic testing to determine that the cause of death was not related to the study. The diagnostic report showed isolation of *P. multocida* and *B. bronchiseptica*.

5. Scientific Justification as to Why Pain and /or Distress Could Not Be Relieved:

Unanticipated circumstances led to unexpected death. All necessary measure were taken to care for the animal

6. Identification of Federal Regulations Requiring This Procedure:

Special Outline 8-021

Initials: (b)(6), (b)(7)(c)

Date: 21 Nov 2012